Loading…
← CockpitCompetitor Analysis › 1501.HK Shanghai INT Medical Instruments Co., Ltd. Class HOpen in the cockpit ↗

Shanghai INT Medical Instruments Co., Ltd. Class H1501.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Medical Specialties
Momentum weak 34
Mkt cap
$700M
US dollars, full cap
Free float
43%
of shares outstanding
$/day
$656,306
20-day average traded
Fwd P/E
15.9×
forward earnings
ROIC−WACC
+3.4 pp
WACC 5.5%
Hurdle
-27 pp
Req g minus delivered
Next earnings
124 days
22 Mar 2027
Close · HKDHK$26.82
1D-7.8%
1W-10.6%
1M-10.9%
3M-20.1%
6M-25.2%
YTD-10.5%
1Y-13.4%
ATR %4.3%
52w lowhigh35.2% off high

What Shanghai INT Medical Instruments does

Employees: 2,088

Shanghai INT Medical Instruments at a glance

Size Shanghai INT Medical Instruments (1501.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $700M, the 666th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$26.82 on 18 Nov 2026.

Performance Over six months the shares fell 25.2%, against -12.4% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 6th lowest of 21 in its peer set.

Growth Revenue grew 34.9% over the last twelve months (peer median +14.1%); the operating margin is 21.3% (peer median 10.6%).

Valuation It trades at 15.9× forward earnings against a peer median of 23.2× (5th cheapest of 17).

Price implies For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is -27 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 3.4 points above its cost of capital (5.5% WACC).

Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 891501.HK 77
Six months, rebased to 100: Shanghai INT Medical Instruments against the median of its 20 peers (local-currency closes).

Shanghai INT Medical Instruments financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$1.34BHK$1.16BHK$924MHK$832MHK$681M
Revenue growth—+25%+11%+22%—
Gross profitHK$816MHK$691MHK$583MHK$484MHK$387M
EBITDAHK$418MHK$353MHK$291MHK$213MHK$172M
Net incomeHK$244MHK$224MHK$208MHK$173MHK$153M
Free cash flowHK$424MHK$310MHK$116MHK$19.7M-HK$73.2M
Capital expenditureHK$77.8MHK$124MHK$180MHK$255MHK$350M
Total debtn/aHK$797MHK$259MHK$104MHK$54.8M

Quarterly statements and history in the cockpit →

Shanghai INT Medical Instruments competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%3012347575688410688085688389300622491000DCTH002876301122688179301367600855300326SNTINMD603108300453QDEL0029501501.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Shanghai INT Medical Instruments is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%0×200×7575688410688085688389300622DCTH002876301122688179300326603108QDEL1501.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shanghai INT Medical Instruments is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%3012347575688410688085688389300622DCTH002876300326SNTINMD1501.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shanghai INT Medical Instruments is the large dot.

Shanghai INT Medical Instruments competitors and peer comparison

How Shanghai INT Medical Instruments compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shanghai INT Medical Instruments against its 20 peers (data as of 18 Nov 2026)
Measure1501.HKPeer medianRank in peer set
1-month return-10.9%-7.3%9th lowest of 21
6-month return-25.2%-12.4%6th lowest of 21
Distance from 52-week high-35.2%-38.3%10th highest of 21
Revenue growth (TTM)+34.9%+14.1%6th highest of 21
Operating margin21.3%10.6%3rd highest of 21
Forward P/E15.9×23.2×5th cheapest of 17
Growth the price implies (Req g, 7 yrs)-3.3%10.1%4th least demanding of 16
Growth delivered (Del g)+23.5%+13.3%5th highest of 16
Hurdle (Req g minus delivered)-26.7 pp-9.8 pp3rd least demanding of 16
ROIC minus cost of capital+3.4 pp+2.7 pp11th highest of 21
EV / EBITDA11.7×9.0×2nd most expensive of 6
Net debt / EBITDA-1.7×-0.6×3rd least indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shanghai INT Medical Instruments 1501.HKHong Kong$700M-25%+35%21%15.9×-3.3%+23.5%
Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZChina$697M+148%-14%3%n/a31.8%-0.6%
Japan Lifeline 7575.TJapan$703M+34%+6%19%14.5×-9.5%+2.9%
SWS Hemodialysis Care 688410.SSChina$706M-11%+31%19%23.5×16.2%+25.9%
Shanghai Sanyou Medical 688085.SSChina$692M-23%+15%4%50.0×29.0%+6.8%
Shenzhen Lifotronic Technology 688389.SSChina$692M-14%+14%13%29.9×11.6%+13.3%
Doctorglasses Chain 300622.SZChina$710M-22%+6%14%22.8×-3.4%+15.7%
Livsmed 491000.KSSouth Korea$687M-47%+89%-77%n/an/an/a
Delcath Systems DCTHUnited States$685M+75%+38%5%358.9×33.4%+120.2%
Shenzhen Sunnypol Optoelectornics 002876.SZChina$680M-9%+29%5%39.0×10.1%+14.2%
Caina Technology 301122.SZChina$721M+36%+61%0%55.4×n/an/a
Shanghai Aladdin Biochemical Technology 688179.SSChina$736M-37%+39%24%27.4×17.1%+24.2%
BMC Medical 301367.SZChina$737M-17%+37%17%18.7×-1.5%+15.6%
Beijing Aerospace Changfeng 600855.SSChina$738M-44%-10%-19%n/an/an/a
Shanghai Kinetic Medical 300326.SZChina$662M-10%-28%17%26.0×6.6%-1.9%
Synektik SNT.WAPoland$662M+10%+32%24%13.8×0.2%+47.5%
InMode INMDUnited States$741M-8%+2%18%9.8×-10.8%+12.4%
Shanghai Runda Medical Technology 603108.SSChina$744M-36%-12%-2%20.5×20.3%-0.2%
Jiang Xi Sanxin Medtec 300453.SZChina$744M-3%+12%18%16.2×-1.9%+11.8%
QuidelOrtho QDELUnited States$657M-20%-5%-2%10.7×n/an/a
Allmed Medical Products 002950.SZChina$747M-32%+14%8%n/an/an/a

Questions

Which companies are Shanghai INT Medical Instruments's closest peers?
The cockpit's peer set: Anhui Hongyu Wuzhou Medical Manufacturer (301234.SZ), Japan Lifeline (7575.T), SWS Hemodialysis Care (688410.SS), Shanghai Sanyou Medical (688085.SS), Shenzhen Lifotronic Technology (688389.SS), Doctorglasses Chain (300622.SZ), Livsmed (491000.KS), Delcath Systems (DCTH).
Is Shanghai INT Medical Instruments expensive compared with its peers?
On forward p/e it trades at 15.9× against a peer median of 23.2×, 5th cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is -27 pp: the price already allows for a slowdown.
How has Shanghai INT Medical Instruments stock performed?
Over six months to 18 Nov 2026 the shares returned -25.2% against -12.4% for the median peer; over one year -13.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.